Úvod: Fibrilace síní (FS) je nejčastější arytmií, jejíž incidence se zvyšuje s věkem; u osob ve věku 50 let se každých deset let zdvojnásobuje a u pacientů ve věku ≥ 80 let dosahuje přibližně 10 %. 1 Přes předvídatelnou farmakokinetiku a farmakodynamiku přímých perorálních antikoagulancií (direct oral anticoagulant, DOAC) je nutno v zájmu účinné a bezpečné léčby, stejně jako pro predikci a detekci trombotických a krvácivých příhod, provádět laboratorní vyšetření, a to i v situacích, kdy by dočasné vysazení léků mohlo být žádoucí. 2 Cíl: Cílem této studie bylo stanovit a analyzovat nutnost provádění koagulačních testů u pacientů s FS a vysokým kardiovaskulárním rizikem v klinické praxi. Metody: V období od října 2016 do června 2017 byla v kardiocentru fakultní nemocnice Pauls Stradins Clinical University Hospital v lotyšské Rize provedena kvantitativní, analytická, průřezová klinická studie. V této studii se shromažďovaly údaje pacientů s nevalvulární FS léčených antikoagulancii po dobu ≥ 3 měsíců, definovaných na základě skóre CHA 2 DS 2 -VASc (≥ 2 nebo 3) jako vysoce riziková skupina mužů i žen. Pro analýzu údajů byl použit software SPSS. Výsledky: Celkem byly získány údaje 143 pacientů, z nichž 46,2 % (n = 66) byli muži; průměrný věk dosahoval 69,7 (SD ± 9,9) roku. Přibližně u dvou třetin (73,1 %) pacientů se FS vyskytovala po dobu více než jednoho roku. Průměrná hodnota skóre CHA 2 DS 2 -VASc byla 4,2 (SD ± 1,5). Nejčastějšími přidruženými onemocněními byly arteriální hypertenze (65,0 %; 93), chronické srdeční selhání (48,3 %; 69), ischemická choroba srdeční (32,9 %; 47), diabetes mellitus (24,5 %; 35) a dyslipidemie (25,9 %; 37). Přibližně polovina (46,2 %; 66) užívala DOAC, z toho 31,5 % rivaroxaban a 14,7 % dabigatran; navíc 1,4 % pacientů užívalo DOAC s antiagregancii. U 71 (49,7 %) pacientů existovalo zvýšené riziko možných lékových interakcí, nejčastěji s inhibitory protonové pumpy (16,8 %; 24), amiodaronem (24,5 %; 35) a protizánětlivými léky (49,0 %; 70). Užívání DOAC a možné lékové interakce zvyšují skóre rizika s maximální hodnotou 3 (16,1 %; 23) a průměrným častým skóre 4,4 u 86 (60,1 %) pacientů s FS. Koncentrace léků v krvi byly nižší, než se očekávalo, a dosahovaly hodnoty přibližně 75,2 % C max . Závěr: Užívání DOAC koreluje se skóre CHA 2 DS 2 -VASc s průměrnou častou hodnotou 4,4 u 86 (60,1 %) pacientů s FS. Koagulační testy pro stanovení koncentrací DOAC v plazmě byly provedeny u více než poloviny pacientů (60,1 %).
Introduction
As the world population ages, the burden of AF (atrial fi brillation) and venous thromboembolism disease is expected to increase, and prescriptions for long-term anticoagulation will climb. 3 AF is associated with signifi cant morbidity, mortality, and socioeconomic burden, particularly form stroke and systemic thromboebolism. The later risks depend on patients age and the presence or absence of various stroke risk factors, which have resulted in the development of clinical scores to aid risk stratifi cation for patients with AF. Anticoagulated patients are vulnerable to spontaneous, traumatic, and perioperative bleeding. Warfarin is a vitamin K antagonist that has been used for decades to prevent and treat arterial and venous thromboembolism. But due to the need of regular monitoring, non-vitamin K antagonists/oral anticoagulants are now widely used as alternatives to warfarin for stroke prevention in atrial fi brillation and management of venous thromboembolism. These are dabigatran etexilate, 4 rivaroxaban, 5 apixaban 6 and edoxaban. 7 DOACs are associated with comparable risk of stroke, systemic embolism, major bleeding and death compared with warfarin. 8 They have more predictable therapeutic effect, pharmacokinetic and pharmacodynamics properties, as well as do not require routine monitoring, have fewer potential drug-drug interactions and no restrictions on dietary requirements. 2 In clinical practice there is still widespread uncertainty on how to manage patients on DOACs who have risk of bleeding. In addition, the lack of specifi c antidotes and measurement methods/assays are critical points for patients' management with AF.
Risk factors on pharmacokinetics and pharmacodynamics of direct oral anticoagulants (DOACs)
The new oral anticoagulants differ in their pharmacology and pharmacokinetics (Table 1) . Although their onset of action and half-life are quite similar, other properties such as their respective mechanism of action, bioavailability, metabolism and creatinine clearance are different. [4] [5] [6] [7] All agents have rapid onset of action, a wide therapeutic window, little or no interaction with food and other drugs, minimal inter-patient variability, and similar pharmacokinetics in different patient populations. Since DOACs are substrates, co-administration with cytochrome P450 system isoenzymes and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations. 2 Clinicians should be aware and take into account before appointment of anticoagulative therapy.
Usually the pharmacokinetic profi le of DOACs in healthy subjects is not substantially affected by age or sex. Patient lifestyle and comorbidities are the main risk factors of anticoagulative therapy. The CHA 2 DS 2 -VASc score (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65-74 years, female) is recommended by guidelines for stroke assessment in AF. 9 Patients with higher CHA 2 DS 2 -VASc score have had a higher risk of stroke, systemic thromboembolism or transient ischemic attack. Taking into account the CHA 2 DS 2 -VASc scale, individuals with extreme body weights may benefi t from dose adjustment to avoid under-or over-anticoagulation (Table 2) . 8 Coagulation tests might be considered upon attainment of stable anticoagulation (1-2 weeks after initiation) to provide the level of anticoagulation achieved chronically. This information could be useful to interpret subsequent results.
Drug anticoagulative levels could be measured occasionally at the time of medical visits to assess adherence to treatment, to detect possible drug interactions, and side effects. It should be realized that given the DOAC with short half-life (e.g. 8-15 hours), a dose missed a few days earlier that testing might not be detected in the laboratory.
The laboratory and direct oral anticoagulants
Although direct oral anticoagulants do not need laboratory testing for dose adjustment, there are instances when Methods: Quantitative, analytic, cross-sectional clinical trial, during the period from October 2016 till June 2017, was performed at Center of Cardiology, Pauls Stradins Clinical University Hospital, Latvia. There were collected data about patients with non-valvular AF, under anticoagulative therapy ≥3 months, defi ned as a high-risk group by CHA 2 DS 2 -VASc score -more or equal to 2 or 3, men and women, respectively. Data were analyzed using SPSS. Results: There were collected data about 143 patients of whom 46.2% (n = 66) were male; the mean age was 69.7 (SD ± 9.9) years. About 2/3 (73.1%) of all patients the AF were longer than 1 year. The mean CHA 2 DS 2 --VASc score was 4.2 (SD ± 1.5). The most common comorbidities were arterial hypertension (65.0%; 93), chronic heart failure (48.3%; 69), coronary artery disease (32.9%; 47), diabetes mellitus (24.5%; 35), and dyslipidemia (25.9%; 37). Almost half of patients (46.2%; 66) used DOACs, 31.5% rivaroxaban and 14.7% dabigatran, respectively; furthermore, 1.4% patients used DOACs with antiaggregants. 49.7% (71) patients had increased risk of possible drug-drug interactions, most frequently with proton pump inhibitors (16.8%; 24), amiodarone (24.5%; 35), anti-infl ammatory drugs (49.0%; 70). The use of DOACs and possible drug--drug interactions increases by risk score, reaching the maximum score 3 (16.1%; 23) and the mean frequent score 4.4 of 86 (60.1%) AF patients, respectively. The drug concentration in blood was lower than expected, reaching about 75.20% of C max . Conclusion: DOACs' usage correlates with CHA 2 DS 2 -VASc score with mean frequent score 4.4 of 86 (60.1%) AF patients, respectively. Coagulation tests were applicable more than half of patients (60.1%) to detect DOACs concentration in plasma. laboratory measurement of the drug anticoagulant effect may be useful. In addition, none of the standard coagulation tests constitutes a sensitive or accurate measure of their therapeutic activity. An assessment of the drug concentration or residual activity could be helpful before initiation of treatment, before surgical or invasive procedures, on occasion of hemorrhagic or thrombotic events, and whenever immediate reversal of anticoagulation is needed. 10 The comparative description of coagulation tests is shown in Table 3 .
Taking into account the different sensitivity and availability of coagulation tests in clinical practice, clinicians should be aware to reduce the risk of bleeding and stroke. According to available data the chromogenic anti-Xa assay and DTI assay are mostly appropriate tests to detect drug concentration and assess the safety of medical therapy and expected effect. Based on available data the coagulative laboratory testing is recommended for patients in high-risk groups, with CHA 2 DS 2 -VASc score ≥3, respectively.
AIM
The aim of this study was to identify and analyze the need of coagulation tests for AF patients with high cardiovascular risk in clinical practice.
Materials and methods
Quantitative, cross-sectional study was conducted at Pauls Stradins Clinical University Hospital, Latvia, in time from January 2013 to April 2015.
Patients were involved based on the following inclusion criteria:
-at least 18 years old; -diagnosed non-valvular (as defi ned by European Society of Cardiology) AF at least in one of the risk evaluation scores (CHA 2 DS 2 -VASc score more or equal to 2); -use DOACs more than 3 months; -have no life-dangerous, serious comorbidities, which can affect patients' mortality (e.g. cancer); -agreed to participate in this research and confi rmed it by signed informed consent form. Main patients' characteristics were collected, e.g. demographic data, comorbidities and used medicines. Laboratory assessments, diagnosis were defi ned during the interview and clarifi ed with doctor if applicable.
Patients' demographic data, disease anamnesis, main comorbidities and used medicines were obtained. Laboratory test results, additional examinations were specifi ed.
On time of data collection the chromogenic anti-Xa assay and DTI assay was introduced at Pauls Stradins Clinical University Hospital. Therefore, additional data about DOAC concentration in plasma were collected as clinical cases and compared with study results.
Results
A total of 143 patients were included in this study, of whom 46.2% (n = 66) were male. The mean age was 69.7 (SD ± 9.9) years. About in two thirds (73.1%) of all patients the AF occurred longer than one year. Almost half of patients (46.2%) used DOACs, 16.1% dabigatran and 33.6% rivaroxaban, respectively. The main characteristics are collected in Table 4 .
The mean CHA 2 DS 2 -VASc score was 4.2 (SD ± 1.5), 3 Table 5 .
According to CHA 2 DS 2 -VASc score, 60.2% patients were in high-risk group: score 3 -23 (16.1%), score 4 -22 (15.4%), score 5 -20 (14.0%) and score 6 -21 (14.7%). The use of DOACs and possible drug-drug interactions increases by risk score, reaching the maximum score 3 (16.1%; 23) and the mean frequent score 4.4 of 86 (60.1%) AF patients, respectively. Based on CHA 2 DS 2 -VASc score and clinically relevant possible drug-drug interactions, the DOACs' concentration in plasma could be affected, in result of increased risk of bleeding and/or thrombotic events. Furthermore, analyzing data by HAS-BLED score, it is shown that 72.7% (104) patients had increased risk of bleeding. The most common comorbidities and their correlation with CHA 2 DS 2 -VASc score is shown in Fig. 1 .
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Patient received rivaroxaban 20 mg twice a day, amiodarone, ramipril, bisoprolol, atorvastatin, amlodipine, etoricoxib and omeprazole. Three hours after use of drug the anticoagulant concentration in blood was 153 ng/ml, what was less than expected -246 ng/ml, respectively. The pharmacokinetic linearity, which is representative to rivaroxaban concentration in blood, was not observed, decreasing only by 5.2%, respectively. The concentration is shown in Fig. 2 .
Taking into account the CHA 2 DS 2 -VASc score, which is 4, and changes in drug concentration in blood, which can affect anticoagulative effect, the patient had increased risk of stroke, systemic thromboembolism or transient ischemic attack.
As shown in clinical cases the drug concentration in blood was lower than expected, reaching about 75.2% of C max . Although there is suffi cient information to generalize the data, however, it was observed that patients with higher CHA 2 DS 2 -VASc score were more complicated and received multiple pharmacotherapy, which could affect DOAC concentration and effect. The study data confi rmed necessity to detect anticoagulants concentration in clinical practice for high-risk patients (CHA 2 DS 2 -VASc score more or equal to 2).
Discussion
The use of DOACs without routine monitoring of anticoagulant effect is likely safe and effective treatment for non-valvular AF in many patients, but there are circumstances, such as treatment failure, bleeding, renal and/ or hepatic failure and perioperative monitoring, in which reliable assays of DOAC activity are needed. DOAC dosing recommendations are currently based on patient characteristics rather than measurement of drug effect, and emerging data from the largest trials of DOACs support this strategy. However, specifi c coagulation assays, depending on the DOACs, should be used in order to provide the more reliable information on plasma concentrations. Standard assays, e.g. aPTT, PT, TT, of anticoagulation are generally insuffi cient for measuring DOAC activity, except in certain circumstances of extremely high or low drug levels and in the case of some factor Xa inhibitors. The use of calibrated chromogenic anti-Xa and DTI assays should be recommended for the assessment of DOACs, factor anti-Xa assay for rivaroxaban, apixaban, and edoxaban, and DTI assay for dabigatran, respectively. Unfortunately global coagulation tests, such as PT and aPTT, are not useful at all and can lead to misinterpretation that could have clinical implications if the result is not fully understood. 11 The use of dedicated assays may probably improve the benefi t-risk profi le of DOACs by identifying poor-and high-responders. Monitoring of therapies may be useful to provide guidance in case of bleeding, thrombosis recurrence, to assess the pharmacodynamics of high-risk groups responders, such as high age, low body weight, low renal function, before urgent surgery or procedure and for those with several comorbidities. However, results should be interpreted with caution if responsiveness is unknown.
Conclusions
DOACs' usage correlates with CHA 2 DS 2 -VASc score with mean frequent score 4.4 of 86 (60.1%) AF patients, respectively. From all high-risk AF patients (score ≥3) 47.7% had potentially moderate or major risk of drug-drug interactions. According to data by HAS-BLED score, it is shown that 72.7% (104) patients had increased risk of bleeding. The drug concentration in blood was lower than expected, reaching about 75.20% of C max . In summary, for 60.1% AF patients appropriate monitoring of anticoagulative therapy should be considered. Anticoagulative laboratory testing for patients on high-risk group could prevent safer anticoagulation therapy for patients with AF.
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